Needham analyst Gil Blum has maintained their neutral stance on STTK stock, giving a Hold rating today.
Gil Blum has given his Hold rating due to a combination of factors related to Shattuck Labs’ current position and future prospects. The company’s pipeline is still in its early stages, which limits the immediate potential for significant value creation. While recent preclinical results for their DR3 targeting monoclonal antibody, SL-325, are promising, they are still in the early phases of development.
Additionally, the anticipated timeline for key milestones, such as the IND submission for SL-325, is set for the third quarter of 2025, with initial clinical results expected in 2026. This indicates that substantial progress and data are still some time away. Moreover, while the company has a solid cash position of $73 million, which can support operations into 2027, the lack of near-term catalysts contributes to the Hold rating, as investors may need to wait for more concrete developments before expecting significant stock movement.
Blum covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Geron, and Cartesian Therapeutics. According to TipRanks, Blum has an average return of -12.7% and a 29.49% success rate on recommended stocks.